Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Tujinpi gel (复方土荆皮凝胶, also transliterated as Fufang Tujingpi Ningjiao) is a traditional Chinese medicine (TCM) topical gel developed and marketed by Hefei Lifang Pharmaceutical (Hefei Lifeon Pharmaceutical). It is a fixed-dose combination formulation containing tujinpi tincture (derived from the bark of *Pseudolarix amabilis* or Golden Larch), benzoic acid, and salicylic acid. The gel is indicated for the topical treatment of superficial fungal skin infections, including tinea pedis (athlete's foot), tinea manuum (hand ringworm), and tinea corporis (body ringworm). Tujinpi provides natural antifungal properties, while benzoic acid and salicylic acid act as keratolytic and antifungal agents to facilitate skin penetration and inhibit fungal growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Tujinpi gel.